Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMI826O)

Drug Name
BP1002 Drug Info
Indication
Disease Entry ICD 11 Status REF
Haematopoietic/lymphoid cancer 2B33.5 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMI826O

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
BCL-2 messenger RNA (BCL2 mRNA) TTFOUV4 BCL2_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
BCL-2 messenger RNA (BCL2 mRNA) DTT BCL2 3.963 4.739 4.146 4.878
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Haematopoietic/lymphoid cancer
ICD Disease Classification 2B33.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
BCL-2 messenger RNA (BCL2 mRNA) DTT BCL2 8.27E-03 0.06 0.13
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04072458) A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Bio-Path Holdings.